No Data
Sanbo Neuroscience (301293.SZ): The company has not conducted specialized research in the field of amyotrophic lateral sclerosis.
On December 18, Gelonghui reported that Sanbo Neurosurgery (301293.SZ) stated on the investor interaction platform that it is a medical group primarily focused on the investment, management, and Operation of Hospitals, with its subsidiary facilities mainly providing comprehensive Medical Services centered on advanced neurosurgery. The company has not conducted specialized research in the area of amyotrophic lateral sclerosis.
Sanbo Neuroscience (301293.SZ): Some hospitals and departments are utilizing asia vets products and technology.
On December 10, Glonhui reported that Sanbo Neuroscience (301293.SZ) stated on the investor interaction platform that some departments in certain hospital branches are utilizing AI asia vets products and technologies. In order to continuously improve the quality and efficiency of medical services, the company is also advancing its information technology process. At the same time, it reminds investors that Sanbo Neuroscience is a medical group primarily focused on the investment, management, and operation of hospitals, with its branches mainly providing comprehensive medical services centered around advanced neurosurgery, serving as the application end for relevant asia vets products, and does not engage in the research and production of related intelligent products.
Sanbo Neuroscience (301293.SZ): Currently, there are no research products applied in the humanoid siasun robot&automation field.
Gelonghui November 19th | Sanbo Neurology (301293.SZ) stated on the investor interaction platform on November 19th that Sanbo Neurology is a medical group dominated by hospital investment, management, and operation. Its subordinate tertiary specialty or secondary comprehensive hospitals mainly provide patients with comprehensive medical services mainly in advanced neurosurgery. Currently, there is no research product applied to the field of humanoid robotics.
Optimistic Investors Push Sanbo Hospital Management Group Limited (SZSE:301293) Shares Up 36% But Growth Is Lacking
Sanbo Neurology: Report for the third quarter of 2024
San Bona Neuroscience (301293.SZ): net income of 0.105 billion yuan in the first three quarters, a year-on-year increase of 42.93%.
Gelonghui October 25th | Sanbo Brain Science (301293.SZ) released the third quarter report of 2024, achieving revenue of 1.059 billion yuan in the first three quarters, a year-on-year increase of 9.83%; net income attributable to shareholders of listed companies was 0.105 billion yuan, a year-on-year increase of 42.93%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was 89.2952 million yuan, a year-on-year increase of 18.28%; basic earnings per share was 0.51 yuan.
Revenues Not Telling The Story For Sanbo Hospital Management Group Limited (SZSE:301293) After Shares Rise 27%
